Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus

Michele Donati, Giovanni Paolino, Luca Muscardin, Chiara Panetta, Pietro Donati

Research output: Contribution to journalArticlepeer-review


Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immuno-suppressed patient without Muir–Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.

Original languageEnglish
Pages (from-to)100-102
Number of pages3
JournalExperimental and Clinical Transplantation
Issue number1
Publication statusPublished - Feb 1 2017


  • Cutaneous tumors
  • Immunosuppressive therapies
  • Muir-Torre syndrome

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus'. Together they form a unique fingerprint.

Cite this